Clinical trial · Observational
A Real-World Study of Bispecific Antibodies in Multiple Myeloma
A Real-World Study of Bispecific Antibodies, Teclistamab and Elranatamab, for Patients With Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bispecific antibody (BsAb) treatments, teclistamab and elranatamab, are newly available for patients with multiple myeloma who are refractory to all current drugs. The results are very encouraging but complicated adverse events, particularly infectious. This study analyzes survival data in patients treated with BsAb, as well as safety data, in particular the proportions and locations of infectious events. The results are compared to a control cohort. This study is multicentric on all the university hospitals of Paris (AP-HP).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Not treated by bispecific antibodies in usual care | Other | — | UNRESOLVED |
| Treated by bispecific antibodies, teclistamab or elranatamab in usual care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Treated by bispecific antibodies
- description
- Patients with multiple myeloma, penta-drug or triple class refractory and treated by bispecific antibodies, teclistamab or elranatamab
- interventionNames
- Other: Treated by bispecific antibodies, teclistamab or elranatamab in usual care
- label
- Control group
- description
- Patients with multiple myeloma, penta-drug or triple class refractory and not treated by bispecific antibodies
- interventionNames
- Other: Not treated by bispecific antibodies in usual care
Primary outcomes (1)
- measure
- Infection rate
- timeFrame
- Up to 18 months
- description
- Explore the infection rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult ≥ 18 years old * Patients with multiple myeloma * Patients who received at least one administration of the following therapies: teclistamab, elranatamab Exclusion Criteria: \- Patients opposed to the collection of their personal data
References
Publications (0)
Data not yet available